Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Status:
Recruiting
Trial end date:
2024-11-02
Target enrollment:
Participant gender:
Summary
- After standard treatment of primary central nervous system lymphoma (PCNSL), high-dose
methotrexate induction therapy, and consolidation therapy, most patients reach complete
remission, but within the first 6 months, 35-60% of patients refractory to treatment or
experience relapse during the first treatment.
- The progression-free survival (PFS) period of relapsed patients is 2.2 months (0-29.6
months), and the survival period is reported as 3.5 months (0-29.6 months). After
relapse, the majority of patients die within 2-4 months due to neurologic deterioration
- Consolidation therapy after induction therapy includes whole-brain radiation therapy,
high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation
(auto-SCT), and high-dose chemotherapy alone.
- However, the median age of the inducing patient is 65 years, and more than half of the
patients who are unable to transplant autologous hematopoietic stem cells (auto-SCT)
after induction therapy account for more than half.
- Therefore, we intend to conduct a study to evaluate the efficacy and safety of
maintenance therapy for rituximab and lenalidomide as one of the consolidation therapies
for patients with primary central nervous system lymphoma (PCNSL).